Interleukin-2 increases activity of sarcoplasmic reticulum Ca2+-ATPase, but decreases its sensitivity to calcium in rat cardiomyocytes

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 2, 2003, Pages 572-580

  Cao, Chun Mei ^a   Xia, Qiang ^a   Bruce, Iain C ^b   Zhang, Xiong ^a   Fu, Chen ^a   Chen, Jun Zhu ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); BINALTORPHIMINE; CAFFEINE; CALCIUM; INTERLEUKIN 2; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST;

AMPLITUDE MODULATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; ELECTROSTIMULATION; ENZYME ACTIVITY; HEART FUNCTION; HEART MUSCLE CELL; INCUBATION TIME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SARCOLEMMA; SARCOPLASMIC RETICULUM;

ADENOSINE TRIPHOSPHATE; ANIMALS; BIOLOGICAL TRANSPORT; CAFFEINE; CALCIUM; CALCIUM CHANNELS, L-TYPE; CALCIUM-TRANSPORTING ATPASES; CYCLIC AMP; HEART; INTERLEUKIN-2; MALE; MYOCARDIUM; MYOCYTES, CARDIAC; NALTREXONE; RATS; RATS, SPRAGUE-DAWLEY; SARCOPLASMIC RETICULUM;

EID: 0037622732     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.048264     Document Type: Article

References (36)

1. Barry WH and Bridge JH (1993) Intracellular calcium homeostasis in cardiac myocytes. Circulation 87:1806-1815.
2. Bers DM (2000) Calcium fluxes involved in control of cardiac myocyte contraction. Circ Res 87:275-281.
3. i transient and contraction in isolated ventricular myocytes of the rat. Pfluegers Arch 443:635-642.
4. Fabiato A (1983) Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol 245:1-14.
5. Farmer BB, Mancina M, Williams ES, and Watanabe AM (1983) Isolation of calcium tolerant myocytes from adult rat hearts: review of the literature and description of a method. Life Sci 33:1-18.
6. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, and Simmons RL (1992) Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science (Wash DC) 257:387-389.
7. Hasenfuss G, Meyer M, Schillinger W, Preuss M, Pieske B, and Just H (1997) Calcium handling proteins in the failing human heart. Basic Res Cardiol 92 (Suppl 1):87-93.
8. Ikemoto N (1982) Structure and function of the calcium pump protein of sarcoplasmic reticulum. Annu Rev Physiol 44:297-317.
9. Inesi G (1985) Mechanism of calcium transport. Annu Rev Physiol 47:573-601.
10. 2+ pump of sarcoplasmic reticulum. Nature (Lond) 342:90-92.
11. Jiang CL, Xu D, Lu CL, Wang YX, You ZD, and Liu XY (2000) Interleukin-2: structural and biological relatedness to opioid peptides. Neuroimmunomodulation 8:20-24.
12. 2+-transport ATPase of cardiac sarcoplasmic reticulum. Biochim Biophys Acta 557:230-242.
13. 2+ pump kinetics from fura 2 measurements. Am J Physiol 267:C1145-C1151.
14. Kodavanti PR, Cameron JA, Yallapragada PR, and Desaiah D (1990) Effect of chlordecone (Kepone) on calcium transport mechanisms in rat heart sarcoplasmic reticulum. Pharmacol Toxicol 67:227-234.
15. 2+ transients and contractile responses of diabetic rat cardiomyocytes. Cardiovasc Res 46:450-462.
16. 2+-ATPase activity in guinea pig ventricles. J Biol Chem 258:464-471.
17. 2+-ATPases in the cardiovascular system during growth and proliferation. Trends Cardiovasc Med 8:75-82.
18. Lompre AM, Anger M, and Levitsky D (1994) Sarco(endo)plasmic reticulum calcium pumps in the cardiovascular system: function and gene expression. J Mol Cell Cardiol 26:1109-1121.
19. Lowry OH, Rosebrough NJ, Farr A, and Randell R (1951) Protein measurement with Folin-phenol reagent. J Biol Chem 193:265-275.
20. Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Duffy JJ, Doetschman T, and Kranias EG (1994) Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ Res 75:401-409.
21. Merritt JE, Jacob R, and Hallam TJ (1989) Use of manganese to discriminate between calcium influx and mobilization from internal stores in stimulated human neutrophils. J Biol Chem 264:1522-1527.
22. 2+ (SERCA)-pumps: link to heart beats and calcium waves. Cell Calcium 25:277-290.
23. Nomura Y, Asano M, Ito K, Uyama Y, Imaizumi Y, and Watanabe M (1997) Potent vasoconstrictor actions of cyclopiazonic acid and thapsigargin on femoral arteries from spontaneously hypertensive rats. Br J Pharmacol 120:65-73.
24. 2+/ calmodulin-dependent phosphorylation or by interaction with phospholamban. J Biol Chem 271:14206-14213.
25. 2+ ATPase in rat heart sarcoplasmic reticulum. Toxicology 129:95-102.
26. Simmerman HK and Jones LR (1998) Phospholamban: protein structure, mechanism of action and role in cardiac function. Physiol Rev 78:921-947.
27. 2+ across the sarcoplasmic reticulum of guinea-pig cardiac cells during excitation-contraction coupling. J Physiol (Lond) 435:605-630.
28. 2+ current. Circ Res 88:195-201.
29. 2+ release from an intracellular pool in myocytes and neurons. Circ Res 70:66-81.
30. Voss J, Jones LR, and Thomas DD (1994) The physical mechanism of calcium pump regulation in the heart. Biophys J 67:190-196.
31. +)-activated adenosine triphosphatase from rat. Anal Biochem 175:284-288.
32. Woo AY, Jiang JM, Chau CF, Waye MM, Cheung WT, Kwan HS, and Cheng CH (2001) Inotropic and chronotropic actions of Ilex latifolia inhibition of adenosine-5′-triphosphatases as a possible mechanism. Life Sci 68:1259-1270.
33. Wu S, Li HY, and Wong TM (1999) Cardioprotection of preconditioning by metabolic inhibition in the rat ventricular myocyte. Involvement of κ-opioid receptor. Circ Res 84:1388-1395.
34. Yew SF, Reeves KA, and Woodward B (1998) Effects of prostaglandin F2α on intracellular pH, intracellular calcium, cell shortening and L-type calcium currents in rat myocytes. Cardiovasc Res 40:538-545.
35. 2+ pathway in the cardiac κ-opioid receptor. Am J Physiol 274:C82-C87.
36. 2+ channel/ ryanodine receptor: modulation by endogenous effectors, drugs and disease states. Pharmacol Rev 49:1-51.